Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 2/20 | 0.57 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.57 |
| ▸ | PTGIR | P43119 | 2/20 | 0.55 |
| ▸ | ACHE | P22303 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.49 |
| ▸ | LPAR5 | Q9H1C0 | 2/20 | 0.49 |
| ▸ | CNR1 | P21554 | 1/20 | 0.49 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.46 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.46 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6715386 | 0.92 | NPC1 (0.61) | PTGESALOX5PTGIRACHENPC1 | |
| SCHEMBL6715335 | 0.92 | PTGES (0.60) | PTGESALOX5PTGIRACHENPC1 | |
| SCHEMBL6719063 | 0.89 | PTGES (0.57) | PTGESALOX5ACHENPC1RAB9A | |
| SCHEMBL6713540 | 0.86 | PTGES (0.54) | PTGESALOX5ACHENPC1RAB9A | |
| SCHEMBL6713643 | 0.83 | PTGES (0.51) | PTGESALOX5ACHENPC1RAB9A | |
| SCHEMBL4560242 | 0.83 | NPC1 (0.60) | PTGESALOX5PTGIRACHENPC1 | |
| SCHEMBL6716683 | 0.82 | ALOX5 (0.54) | PTGESALOX5LPAR1LPAR5AOC3 | |
| SCHEMBL5515925 | 0.80 | PTGES (0.53) | PTGESALOX5PTGIRACHENPC1 | |
| SCHEMBL6715324 | 0.80 | ALOX5 (0.48) | PTGESALOX5ACHENPC1RAB9A | |
| SCHEMBL6715318 | 0.80 | ALOX5 (0.48) | PTGESALOX5ACHENPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040192685-A1 | Tetrahydroisoquinoline compounds as estrogen agonists/antagonists | CAMERON KIMBERLY O (US) | 2004-09-30 | — | — | US | disclosed |
| US-20030220494-A1 | Tetrahydroisoquinoline compounds as estrogen agonists/antagonists | CAMERON KIMBERLY O (US) | 2003-11-27 | — | — | US | disclosed |
| US-6608203-B2 | Devoid of unwanted side effects | PFIZER INC. | 2003-08-19 | — | — | US | disclosed |
| US-20010039285-A1 | Tetrahydroisoquinoline compounds as estrogen agonists/antagonists | CAMERON KIMBERLY O (US) | 2001-11-08 | — | — | US | disclosed |
| EP-1113007-A1 | Tetrahydroisoquinoline compounds as estrogen agonists/antagonists | PFIZER INC. (US) | 2001-07-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010039285-A1 | Tetrahydroisoquinoline compounds as estrogen agonists/antagonists | GPER1, ESR1, ESR2 | PTGES 181/4885ALOX5 644/4885PTGIR 202/4885 |
| US-20030220494-A1 | Tetrahydroisoquinoline compounds as estrogen agonists/antagonists | GPER1, ESR1, ESR2 | PTGES 181/4885ALOX5 644/4885PTGIR 202/4885 |
| US-20040192685-A1 | Tetrahydroisoquinoline compounds as estrogen agonists/antagonists | GPER1, ESR1, ESR2 | PTGES 181/4885ALOX5 644/4885PTGIR 202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.